Conflict of interest statement: S.J. served as a consultant for Bristol Myers 
Squibb (BMS), Janssen, Legend Biotech, Sanofi, and Takeda. Y.L. served as a 
consultant for Kite/Gilead, Celgene (a BMS Company), Juno Therapeutics (a BMS 
Company), bluebird bio, Janssen, Legend Biotech, Gamida Cells, and Novartis; 
received research funding from Kite/Gilead, Celgene (a BMS Company), bluebird 
bio, Janssen, Merck, and Takeda; is a member of Sorrento Therapeutics Data and 
Safety Monitoring Board. H.G. received grants and/or provision of 
investigational medicinal product from Amgen, BMS, Celgene (a BMS Company), 
Chugai, Dietmar-Hopp-Foundation, Janssen, Johns Hopkins University, and Sanofi; 
received research funding from Amgen, BMS, Celgene (a BMS Company), Chugai, 
Janssen, Incyte, Molecular Partners, Merck, Sharp and Dohme, Sanofi, 
Mundipharma, Takeda, and Novartis; served as a member of advisory board for 
Adaptive Biotechnologies, Amgen, BMS, Janssen, Sanofi, and Takeda; participated 
in the speakers’ bureau for Amgen, BMS, Celgene (a BMS Company), Chugai, 
GlaxoSmithKline (GSK), Janssen, Novartis, and Sanofi. D.R. served as a 
consultant for Celgene (a BMS Company), Janssen, Takeda, Amgen, and Karyopharm; 
received honoraria from Celgene (a BMS Company), Janssen, Takeda, and Amgen; 
received research funding from Celgene (a BMS Company), Janssen, Takeda, Otsuka, 
Merck, and BMS; provided expert testimony for Celgene (a BMS Company) and Amgen. 
A.N. served as a consultant for Spectrum Pharmaceuticals, BMS, Adaptive 
Biotechnologies, Amgen, Celgene (a BMS Company), Takeda, Karyopharm, 
Oncopeptides, GSK, and Janssen; received research funding from BMS, Amgen, 
Celgene (a BMS Company), Takeda, Karyopharm, GSK, and Janssen. P.R.O. served as 
a consultant for Celgene (a BMS Company), Janssen, AbbVie, Kite Pharma, and 
Sanofi; participated in the speakers’ bureau for Celgene (a BMS Company), 
Janssen, and Amgen; received travel funding from Celgene (a BMS Company). K.M. 
received honoraria from Celgene (a BMS Company), Takeda, and Janssen. N.S. 
served as a consultant for Genentech, Seagen Inc., Oncopeptides, Karyopharm, 
Surface Oncology, Precision Biosciences, GSK, Nektar, Amgen, Indapta 
Therapeutics, Sanofi, and BMS; received research funding from Celgene (a BMS 
Company), Janssen, bluebird bio, Sutro Biopharma, and Teneobio. L.D.A. served as 
a consultant for Amgen, BMS, GSK, Janssen, and Karyopharm; received research 
funding and honoraria from GSK, BMS, Janssen, Karyopharm, and Amgen. K.W., 
H.V.L., A.A. are employees and equity owners with BMS. A.S.S. was an employee of 
BMS at the time the work was completed. D.S.S. served as a consultant for Amgen, 
Celgene (a BMS Company), Takeda, Janssen, BMS, Karyopharm, and Merck; 
participated in the speakers’ bureau for Amgen, Celgene (a BMS Company), Takeda, 
Janssen, and BMS; received research funding from Celgene (a BMS Company); is an 
equity owner with Celularity. A.S., R.P., and M.S. declare no conflict of 
interest.